QualityStocksNewsBreaks Archives - Page 3 of 1626

ThursdaySep 10, 2026 12:17 pm

QualityStocksNewsBreaks – Earth Science Tech Inc.’s (ETST) B2B-B2C Healthcare Platform Powers Continued Revenue Growth

Earth Science Tech (OTC: ETST) is positioning itself as a vertically integrated healthcare company through its subsidiaries RxCompoundStore, Mister Meds, and Peaks Curative, combining compounding pharmacy, telemedicine, clinical support, and fulfillment capabilities. Its B2B and B2C business model allows the company to serve independent clinics while also selling customized medications directly to consumers, creating diversified revenue streams across physical and digital healthcare operations. In FY2026, ETST reported revenue of $35.7 million, up from $33.1 million in FY2025 and $11.95 million in FY2024, while also reporting positive operating cash flow and a stronger balance sheet. The company reduced total liabilities from $3.146…

ThursdaySep 10, 2026 10:10 am

QualityStocksNewsBreaks – SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) (Frankfurt: 5OV0) Launches Overwatch Patrol for GPS-Denied Dismounted Operations

This article has been disseminated on behalf of SPARC AI Inc. and may include paid advertising. SPARC AI (CSE: SPAI) (OTCQB: SPAIF) (Frankfurt: 5OV0) launched Overwatch Patrol, a dismounted positioning application designed to provide continuous location information to soldiers and security personnel when GPS is jammed, spoofed, degraded or unavailable. Unveiled at the International Defense Industry Exhibition (“MSPO”) in Kielce, Poland, Overwatch Patrol operates through the company’s cloud-based Overwatch Positioning Network without additional hardware and can be delivered through a native application or standard web browser. The platform enables multiple team members to share live positions without GPS and allows…

ThursdaySep 10, 2026 10:00 am

QualityStocksNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) is advancing Lucid-MS toward a randomized, double-blind, placebo-controlled phase 2 trial in multiple sclerosis (“MS”) following U.S. Food and Drug Administration (“FDA”) clearance of its Investigational New Drug (“IND”) application. Lucid-MS is a patented, first-in-class, non-covalent inhibitor of peptidyl arginine deiminase 2 (“PAD2”) designed to target demyelination directly rather than suppress the immune system. The editorial also highlights Quantum BioPharma research collaboration with Massachusetts General Hospital and Harvard Medical School involving the [¹⁸F]3F4AP PET imaging tracer, which is being evaluated as a…

ThursdaySep 10, 2026 9:52 am

QualityStocksNewsBreaks – American Fusion Inc. (OTC: AMFN) Highlights Texatron(TM) Fusion Engine(TM) Development, AI Power Strategy in New Interview

American Fusion (OTC: AMFN) announced the release of a new AGORACOM interview featuring Executive Chairman Brent Nelson discussing development of the company proprietary Texatron(TM) Fusion Engine(TM) and its strategy for addressing growing electricity demand from artificial intelligence, data centers and other power-intensive applications. Nelson discusses the company 5 MW preproduction Texatron(TM), plans for 10 MW and 20 MW systems and Texas authorization to test 12 planned system sizes ranging from approximately 500 kW to 1 GW, while noting the ratings are intended system sizes and not demonstrated electrical output. American Fusion is targeting documented test results demonstrating the Texatron(TM) can generate and capture sufficient energy for conversion into usable electricity, with…

ThursdaySep 10, 2026 9:50 am

QualityStocksNewsBreaks – SS Innovations International, Inc. (NASDAQ: SSII) Reports 79% Growth in SSi Mantra Procedures, Expands Global Reach

SS Innovations International (NASDAQ: SSII) provided an update on the continued expansion and utilization of its SSi Mantra surgical robotic system, reporting 14,103 cumulative procedures as of Sept. 8, 2026, up 79% from 7,885 at year-end 2025, while its installed base increased 42% to 238 systems from 168. The SSi Mantra is now installed across 12 countries, approximately 1,500 physicians have been trained on the platform and the system has been used for more than 170 types of surgical procedures. Recent international milestones include the launch of robotic cardiac surgery in Colombia, installation of the first SSi Mantra in Sri…

ThursdaySep 10, 2026 9:36 am

QualityStocksNewsBreaks – SuperQ Quantum Computing Inc. (CSE: QBTQ) (OTCQB: QBTQF) (FSE: 25X) Advances Super Nova(TM) Modular Hybrid Quantum Computer

This article has been disseminated on behalf of SuperQ Quantum Computing Inc. and may include paid advertising. SuperQ Quantum (CSE: QBTQ) (OTCQB: QBTQF) (FSE: 25X) is actively developing its flagship Super Nova(TM) modular hybrid quantum computer, with the quantum hardware layer being developed at the University of Waterloo Digital Quantum Matter Lab under the supervision of superconducting quantum physics expert Professor Matteo Mariantoni. Designed to integrate with enterprise IT and high-performance computing infrastructure, Super Nova(TM) combines quantum hardware with classical CPUs and GPUs to address cost, operating-system and interoperability barriers to broader quantum computing adoption. SuperQ is also expanding its Waterloo technical team through the recruitment of multiple quantum hardware scientists focused…

ThursdaySep 10, 2026 9:10 am

QualityStocksNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO)(OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) CMO Discusses ONC010, Novel PNKP Target in BioMedWire Podcast

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) Chief Medical Officer Dr. Islam Mohamed joined IBN BioMedWire Podcast to discuss lead drug candidate ONC010, the company novel approach to targeting the DNA repair enzyme polynucleotide kinase phosphatase (“PNKP”) and its planned first-in-human clinical program. Mohamed highlighted ONC010 two selectivity mechanisms — synthetic lethality designed to limit drug lethality to cancer cells that have lost PTEN or SHP-1 and nanoparticle delivery intended to concentrate the drug within tumor tissue — as well as preclinical…

ThursdaySep 10, 2026 9:00 am

QualityStocksNewsBreaks – Lahontan Gold Corp. (TSXV: LG) (OTCQB: LGCXF) Appoints Billy Choi as Chief Financial Officer

This article has been disseminated on behalf of Lahontan Gold Corp. and may include paid advertising. Lahontan Gold (TSXV: LG) (OTCQB: LGCXF) announced it has hired Billy Choi as its new chief financial officer, with Choi expected to assume full CFO responsibilities in October 2026 following a transition period. Choi most recently served as vice president of finance at Lithium Royalty Corp., where he was involved in its initial public offering, public-company reporting, financial controls and subsequent acquisition by Altius Minerals. Lahontan said the appointment strengthens its financial management team as the company advances permitting for the Santa Fe Mine…

WednesdaySep 09, 2026 10:38 am

QualityStocksNewsBreaks – LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) Appoints Andrew Elinesky CEO, Advances Trafigura Due Diligence

This article has been disseminated on behalf of LaFleur Minerals and may include paid advertising. LaFleur Minerals (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) announced the appointment of Andrew Elinesky as CEO, effective immediately, and provided updates on its Beacon Gold Mill and Trafigura Canada Limited due diligence for proposed prepayment and gold doré offtake arrangements. Elinesky brings more than two decades of senior executive and financial leadership experience and most recently served as president and CEO of Sabre Gold Mines Corp., which was acquired in February 2025. He will oversee corporate strategy, capital markets, financing and investor relations, while former CEO Paul Ténière will continue as president and a director and oversee…

WednesdaySep 09, 2026 9:37 am

QualityStocksNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Featured in BioMedWire Editorial Following FDA Clearance for Lucid-MS Phase 2 Trial

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) announced its placement in a BioMedWire editorial examining the company’s Lucid-MS drug candidate and its recent FDA clearance to begin a phase 2 clinical trial. The editorial, “A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach,” highlights Lucid-MS as a patented, first-in-class candidate designed to protect and potentially repair the myelin sheath rather than target the immune system and notes that the milestone has drawn a new buy rating from Wall Street analysts. To view the full press release, visit https://ibn.fm/swDBz About Quantum BioPharma Ltd. Quantum is a…

Site Search

Company Search

Category: QualityStocksNewsBreaks